Filtered By:
Cancer: Leukemia
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 341 results found since Jan 2013.
WIRED Health 2017 London: Looking Into The Future of Healthcare
Last week WIRED Health gathered hundreds of leaders and influencers from across the globe in London to discuss the field of health innovation and technology. In addition to their long lists of honors and historic accolades, the unrivaled lineup of s...
Source: Medgadget - March 16, 2017 Category: Medical Equipment Authors: Tom Peach Tags: Exclusive Source Type: blogs
New study: polydatin blasts myeloma cells to smithereens
Discussion part, where the researchers state that polydatin was found to be less toxic to normal cells. Does that mean it was somewhat toxic to normal cells, though less so, compared to cancer cells? I couldn’t find an answer…can anyone else find it?
Reading on, we see that polydatin (or PD, for short), “functioned as a tumor suppressor in MM cells. The proliferation of MM cells decreased and apoptosis increased progressively along with the increasing concentrations of PD.” Super duper…again.
The study concludes that “PD effectively suppressed cell growth and induced apoptosis and auto...
Source: Margaret's Corner - March 9, 2017 Category: Cancer & Oncology Authors: Margaret Tags: Blogroll cancer Japanese knotweed myeloma polydatin Source Type: blogs
Chimeric Antigen Receptor Cancer Immunotherapies Continue to Look Promising
Cancer treatments based on the use of chimeric antigen receptors are one of the more promising of present forms of immunotherapy. In trials they are producing good results in patients with late stage leukemia and lymphoma, who lack any other options, and are comparatively fragile and beaten down by the combination of disease and prior aggressive treatments. They should do even better once deployed earlier, for patients who have not run this gauntlet. In cancer, as in many things, the earlier the intervention the better the prognosis.
Six months after receiving infusions of their own T cells - genetically engineere...
Source: Fight Aging! - March 3, 2017 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
The Future Of Precision Medicine: Great Promise, Significant Challenges
Editor’s note: This post is part of a series stemming from the Fifth Annual Health Law Year in P/Review event held at Harvard Law School on Monday, January 23rd, 2017. The conference brought together leading experts to review major developments in health law over the previous year, and preview what is to come.
In his 2015 State of the Union address, President Obama launched the Precision Medicine Initiative (PMI), which is intended to help move medicine from the traditional “one-size-fits-all” approach where treatments are designed for the “average” patient, to one that “takes into account individual diffe...
Source: Health Affairs Blog - February 28, 2017 Category: Health Management Authors: Jonathan Darrow, Aaron Kesselheim and Jessica Lasky-Su Tags: Costs and Spending Featured Quality 21st Century Cures Act cancer moonshot cancerr Precision Medicine Research The Health Law Year in P/Review Source Type: blogs
What pediatricians should know about bone marrow failure syndromes
Pediatricians face a difficult task determining when to refer a child for a suspected bone marrow failure syndrome. We now realize that only a subset of children with bone marrow failure syndromes present with the findings described in textbooks. These children often appear well and lack classical physical stigmata. By the time they look sick, their marrow’s ability to produce blood cells can be so weakened that it could be too late — or at least much more difficult — to treat them successfully.
These rare disorders can range from life-threatening conditions requiring a hematopoietic stem cell transplant to...
Source: Kevin, M.D. - Medical Weblog - February 28, 2017 Category: Journals (General) Authors: < a href="http://www.kevinmd.com/blog/post-author/akiko-shimamura" rel="tag" > Akiko Shimamura, MD, PhD < /a > Tags: Conditions Cancer Source Type: blogs
Induced Pluripotency as a Tool to Enable Rejuvenation of Blood Production
It has been a decade or so since the first induced pluripotent stem (iPS) cells were produced. Researchers discovered a recipe by which ordinary, limited, adult somatic cells could be reprogrammed into a state near identical to that of embryonic stem cells, meaning they are pluripotent and can then in principle be used to produce any of the cell types in the body. Doing so in practice requires researchers to establish a suitable methodology to guide cellular differentiation in the right direction, only accomplished at this point for a fraction of all possible cell types. The early attempts at induced pluripotency worked, a...
Source: Fight Aging! - February 24, 2017 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
A Million Jobs in Healthcare ’ s Future
By PRAVEEN SUTHRUM
“The Future is Here. It’s Just Not Evenly Distributed.”
It’s true.
Science fiction writer William Gibson said that right. We simply have to look around enough – now – to find out what the future holds.
The future may never be evenly distributed. But it’s surely becoming the present faster.
What would you do when…
Here are a series of what-would-you-do-when questions to think about. Each of these are a reality today, somewhere.
There’s more medical data than insight
Kaiser Permanente presently manages 30 petabytes of data. Images. Lab tests. EHRs. Pat...
Source: The Health Care Blog - February 21, 2017 Category: Consumer Health News Authors: John Irvine Tags: Tech Uncategorized Source Type: blogs
Younger than 76 Years-Old? Turns Out You Won ’t Die from Occupational Radiation
Safety conditions have come a long way in radiology. Back in the day, radiologists who graduated before 1940 were susceptible to increased mortality rates from diseases such as myeloid leukemia, myelodysplastic syndrome, melanoma, and non-Hodgkin ’s lymphoma, all conditions related to radiation exposure. Before the emerging of technical advancements in machinery and radiation protection, radiologists were more frequently exposed to low and moderate doses of radiation, and thus in danger of developing serious ailments and disorders. Yet, sa fety has greatly improved over the last half of the 20th century, say researchers ...
Source: radRounds - February 15, 2017 Category: Radiology Authors: Julie Morse Source Type: blogs
Socialized Medicine: From Anecdote to Data
Last night ’s CNN duel between Senators Bernie Sanders and Ted Cruz on the future of Obamacare was pretty illuminating for a recent arrival to the United States, with Senator Sanders’ playbook all-too-familiar to those of us from the UK.Sanders wants a single-payer socialized healthcare system in the United States, just as we have in Britain. Any objection to that is met with the claim that you are “leaving people to die.” The only alternatives on offer, you would think, are the U.S. system as it exists now, or the UK system. Sanders did not once acknowledge that the UK structure, which is free at the point of use,...
Source: Cato-at-liberty - February 8, 2017 Category: American Health Authors: Ryan Bourne Source Type: blogs
How do I fix communication with my patients?
There is a basic communication gap between you and me. How could there not be? It’s not what you expect. I say you have cancer, or heart failure, or emphysema. Full stop. A conversation ensues. This is not what I’m talking about.
It’s more like when I report to you a series of normal lab results, and at the end flippantly mention a slight elevation of the white blood cell count. In my mind, it is a minor issue and likely due to that viral infection that you are recovering from. As the days pass, my words simmer and eventually come to a boil, consuming you. The elevation could be leukemia after all. You co...
Source: Kevin, M.D. - Medical Weblog - February 6, 2017 Category: Journals (General) Authors: < a href="http://www.kevinmd.com/blog/post-author/jordan-grumet" rel="tag" > Jordan Grumet, MD < /a > Tags: Physician Primary care Source Type: blogs
What It Means to Be Your Own Patient Advocate
I learned what it means to be a patient advocate many years ago, when my dad was sick. We knew something was terribly wrong with this tall, strapping man when he started to lose weight and was continually fatigued. Our frustration grew as each time he went to the doctor, he came home with instructions to quit smoking.
Fighting for My Father
Patient advocacy often means working around the doctor, so I found a clinic in Toronto that would perform every test known to man to determine my dad’s illness. Thanks to the Canadian healthcare system, it wasn’t going to cost my dad anything. We quickly learned that he had non-Ho...
Source: Life with Breast Cancer - January 23, 2017 Category: Cancer & Oncology Authors: Kathy-Ellen Kups, RN Tags: Breast Cancer Source Type: blogs
And You Will Answer
There is a basic communication gap between you and I. How could there not be? It's not what you expect. I say you have cancer, or heart failure, or emphysema. Full stop. A conversation ensues. This is not what I'm talking about.It's more like when I report to you a series of normal lab results, and at the end flippantly mention a slight elevation of the white blood cell count. In my mind, it is a minor issue and likely do to that viral infection that you are recovering from. As the days pass, my words simmer and eventually come to a boil, consuming you. The elevation could be le...
Source: In My Humble Opinion - January 1, 2017 Category: Primary Care Authors: Jordan Grumet Source Type: blogs
Chimeric Antigen Receptor Therapy Continues to Perform Well in Lymphoma Patients
We report here the safety, efficacy, and correlative studies of apheresis product, KTE-C19, and in vivo effects from the phase 1 portion of ZUMA-1.
As of August 2016, the median follow-up time was 9 months. Nine patients were enrolled in the study. Two patients experienced adverse events due to disease progression, discontinued the study, and never received KTE-C19. Seven patients received conditioning chemotherapy and KTE-C19. Patients ranged from 29 to 69 years of age and had received two to four prior lines of therapy. Three were refractory to second-line or later lines of therapy, and four patients had relapsed ...
Source: Fight Aging! - December 30, 2016 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
December Supporter of the Month: Pam Whitehead
Our “Supporter of the Month” initiative was designed to recognize our donors, volunteers, and fundraisers and share their stories with our staff, interns, clients, and visitors. Pam is a cancer survivor and over the past 5 years, has served as a LIVESTRONG Leader. She works as an architect at her own firm and created her own foundation, Triumph Cancer Foundation.LS: How did you become involved with LIVESTRONG?Pam: I was diagnosed with uterine cancer in 2000. I was 36, and at that time the cancer landscape was very different. I didn ’t know anyone my age who had cancer, or even anyone with uterine cancer. There was ve...
Source: LIVESTRONG Blog - December 15, 2016 Category: Cancer & Oncology Authors: LIVESTRONG Staff Source Type: blogs
